Vanguard Group Inc. Has $454.77 Million Stock Position in Vaxcyte, Inc. $PCVX

Key Points

• Vanguard Group Inc. has increased its stake in Vaxcyte, Inc. by 0.7%, now owning about 12 million shares valued at approximately $454.8 million.
• Vaxcyte received positive analyst ratings, with ten analysts rating it a buy and a consensus price target of $136.50.
• Despite reporting a quarterly loss of ($1.22) EPS, the company's stock showed a modest gain of 4.0% recently, with current shares trading at $32.70.

Vanguard Group Inc. raised its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 0.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,043,805 shares of the company's stock after acquiring an additional 82,118 shares during the quarter. Vanguard Group Inc. owned about 9.34% of Vaxcyte worth $454,774,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Capital Research Global Investors increased its position in Vaxcyte by 26.8% in the 4th quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock valued at $508,393,000 after acquiring an additional 1,312,302 shares in the last quarter. Paradigm Biocapital Advisors LP boosted its stake in shares of Vaxcyte by 57.3% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company's stock valued at $116,469,000 after purchasing an additional 518,255 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of Vaxcyte by 5.6% in the 4th quarter. Deutsche Bank AG now owns 1,212,706 shares of the company's stock valued at $99,272,000 after purchasing an additional 64,522 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Vaxcyte by 11.9% in the 4th quarter. Northern Trust Corp now owns 1,160,001 shares of the company's stock valued at $94,958,000 after purchasing an additional 123,584 shares during the last quarter. Finally, Woodline Partners LP boosted its stake in shares of Vaxcyte by 1.5% in the 4th quarter. Woodline Partners LP now owns 1,120,922 shares of the company's stock valued at $91,759,000 after purchasing an additional 16,977 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Vaxcyte Stock Down 1.5%

Vaxcyte stock traded down $0.47 during midday trading on Wednesday, hitting $31.26. 1,151,561 shares of the stock were exchanged, compared to its average volume of 1,334,744. The company has a fifty day simple moving average of $33.74 and a two-hundred day simple moving average of $45.46. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06. The stock has a market capitalization of $4.06 billion, a PE ratio of -7.61 and a beta of 1.21.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period last year, the company earned ($1.10) EPS. As a group, equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PCVX. Cantor Fitzgerald began coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Cowen reaffirmed a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company's stock. According to data from MarketBeat.com, Vaxcyte has an average rating of "Buy" and an average price target of $136.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.